

- changes in gene expression in pulmonary arteries. *Lab. Invest.* 82, 1391–1398.
26. Wright, J.L., Tai, H., and Churg, A. 2004 Cigarette smoke induces persisting increases of vasoactive mediators in pulmonary arteries. *Am. J. Respir. Cell Mol. Biol.* 31, 501–509.
 27. Torsney, E., Charlton, R., Parums, D., Collis, M., Arthur, H.M., Si, C.D., Si, C.D., Si, C.D., Si, C.D., and Si, C.D. 2002. Inducible expression of human endoglin during inflammation and wound healing in vivo. *Inflamm. Res.* 51, 464–470.
 28. Rossi, E., Sanz-Rodriguez, F., Eleno, N., Düwell, A., Blanco, F.J., Langa, C., Botella, L.M., Cabañas, C., Lopez-Novoa, J.M., and Bernabeu, C. 2013. Endothelial endoglin is involved in inflammation: Role in leukocyte adhesion and transmigration. *Blood* 121, 403–415.
 29. Santos, S., Peinado, V.I., Ramírez, J., Melgosa, T., Roca, J., Rodriguez-Roisin, R., and Barberà, J.A. 2002. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. *Eur. Respir. J.* 19, 632–638.
 30. Torsney, E., Charlton, R., Diamond, A.G., Burn, J., Soames, J. V., and Arthur, H.M. 2003. Mouse model for hereditary hemorrhagic telangiectasia has a generalized vascular abnormality. *Circulation* 107, 1653–1657.
 31. Hassoun, P.M., Mouthon, L., Barberà, J.A., Eddahibi, S., Flores, S.C., Grimminger, F., Jones, P.L., Maitland, M.L., Michelakis, E.D., Morrell, N.W., et al. 2009. Inflammation, Growth Factors, and Pulmonary Vascular Remodeling. *J. Am. Coll. Cardiol.* 54, .
 32. Eddahibi, S., Guignabert, C., Barlier-Mur, A.M., Dewachter, L., Fadel, E., Dartevielle, P., Humbert, M., Simonneau, G., Hanoun, N., Saurini, F., et al. 2006. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: Critical role for serotonin-induced smooth muscle hyperplasia. *Circulation* 113, 1857–1864.
 33. Ashwell, M., and Gibson, S. 2016. Waist-to-height ratio as an indicator of early health risk: Simpler and more predictive than using a matrix based on BMI and waist circumference. *BMJ Open* 6, .
 34. Hammod, H.J., Al-Dujaili, A.N., and Al-Dujaili, M.N. 2016. Relationship between adipocyte fatty acid-binding protein in obese men with cardiovascular diseases. *Res. J. Pharm. Biol. Chem. Sci.* 7, 804–808.
 35. Hammod, H.J., Al-Dujaili, A.N., and Al-Dujaili, M.N. 2016. The Correlation between cardiovascular diseases in obese men with the inflammatory markers: Dyslipidemia, C-reactive protein and tumor necrosis factor- α . *Res. J. Pharm. Biol. Chem. Sci.* 7, 809–814.
 36. Taichman, D.B., and Mandel, J. 2007. Epidemiology of Pulmonary Arterial Hypertension. *Clin. Chest Med.* 28, 1–22.
 37. Burger, C.D., Foreman, A.J., Miller, D.P., Safford, R.E., McGoon, M.D., and Badesch, D.B.(2011. Comparison of body habitus in patients with pulmonary arterial hypertension enrolled in the registry to evaluate early and long-term PAH disease management with normative values from the national health and nutrition examination survey. *Mayo Clin. Proc.* 86, 105–112.
 38. Taraseviciute, A., and Voelkel, N.F. 2006. Severe pulmonary hypertension in postmenopausal obese women. *Eur. J. Med. Res.* 11, 198–202.
 39. Leone, N., Courbon, D., Thomas, F., Bean, K., Jego, B., Leynaert, B., Guize, L., and Zureik, M. 2009. Lung function impairment and metabolic syndrome: the critical role of abdominal obesity. *Am. J. Respir. Crit. Care Med.* 179, 509–516.
 40. Zeng, W., Sun, Y., Gu, Q., Xiong, C., Li, J., and He, J. 2012. The impact of pulmonary arterial hypertension-targeted therapy on survival in Chinese patients with idiopathic pulmonary arterial hypertension. *Pulm. Circ.* 2, 373–378.